Roger Williams Medical Center a CharterCare Health Partner Presenter: Mark Curtis RPh Clinical Informatics Pharmacist.

Slides:



Advertisements
Similar presentations
1 Accurate BP measurement in the diagnosis of hypertension Introduction to AOBP (Automated Office Blood Pressure) Mark Gelfer, MD.
Advertisements

Who, What and When: Transplant for Acute Lymphoblastic Leukemia Brandon Hayes-Lattin September 13, 2013.
EPrescribing of Chemotherapy The Leeds Experience Julie Mansell, Lead Chemotherapy Pharmacist, Leeds Cancer Centre.
Activity Faculty Luciano J. Costa, MD, PhD Associate Professor of Medicine Department of Medicine and UAB-CCC Bone Marrow Transplantation and Cell Therapy.
Systems Based Practice and Practice Based Learning. How to teach? How to evaluate? Deborah J. DeWaay M.D. Hospitalist/Clerkship Director, General Internal.
DEVELOPMENT AND IMPLEMENTATION OF CHEMOTHERAPY ORDER TEMPLATES IN CPRS
Activity Faculty Scott C. Howard, MD, MSc University of Tennessee College of Health Sciences Memphis, TN.
BY DR IHEANACHO O.E..  Biodata  Male, 15years, student.  Diagnosis  SCA  Treatment  HSCT  HLA-matched sibling donor.  RIC using Flu/Bu.
Copyright © 2009 Wolters Kluwer Health | Lippincott Williams & Wilkins Chapter 05: Relieving Pain and Providing Comfort.
Instructions say P.O. q 4 h prn pain.
Dosages Based on Body Weight
Calculating Pediatric Dosage
MabThera ® and Autologous Stem Cell Transplant (ASCT)
MEDICATION THERAPY MANAGEMENT SERVICES Getting the most from your medicine.
O NCOLOGY P HARMACY P RACTICE Anna Solomon, RPh, PharmD, BCPS Full Time Facilitator, HSOP.
Medication Error Nasha’at Jawabreh And yousef. What is the definition of medication error ?
DR. YETUNDE T. ISRAEL-AINA PAEDIATRICIAN, UNIVERSITY OF BENIN TEACHING HOSPITAL, BENIN CITY BENIN BLOOD AND MARROW TRANSPLANT WORKSHOP, UNIVERSITY OF BENIN.
LIBYAN EXPERIENCE IN PEDIATRIC ACUTE MYELOID LEUKEMIA Fathia El Riani, Rasem Al Ajnef, Elham Sbita, Salem Zarroug Departement of pediatric hematology-oncology.
 BSA (m 2 ) = √ Ht(in) X wt (lb) 3131 Ht (cm) X wt (kg) 3600 Mosteller,RD " Simplified Calculation of Body Surface Area", N Engl J Med 1987, 317 (17):
Transfusion requirements in autologous stem cell transplantation: a single-center-experience Sousse
Alternating Courses of CHOP and DHAP Plus Rituximab (R) Followed by a High-Dose Cytarabine Regimen and ASCT is Superior to Six Courses of CHOP Plus R Followed.
Reduced-Intensity Conditioning (RIC) and Allogeneic Stem Cell Transplantation (allo-SCT) for Relapsed/Refractory Hodgkin Lymphoma (HL) in the Brentuximab.
ANCO ASH 2005 Review Acute Leukemias Feb 22, 2006 Charles Linker MD.
Copyright © 2009 Wolters Kluwer Health | Lippincott Williams & Wilkins Chapter 10 Dosage Problems for Infants and Children.
Optimizing Timing of Transplant in Hodgkin Lymphoma Ginna G. Laport, MD Associate Professor of Medicine Division of Blood & Marrow Transplantation Stanford.
DLBCL with less than PR to second line therapy… Correcting a Misconception…. Koen van Besien, MD Weill Cornell Medical College, NY.
C-1 Pegfilgrastim (Neulasta  ) Oncologic Drugs Advisory Committee Pediatric Subcommittee October 20, 2005 Amgen Inc.
Margaret L. Green, Wendy M. Leisenring, Hu Xie, Roland B. Walter, Marco Mielcarek, Brenda M. Sandmaier, Stanley R. Riddell and Michael Boeckh Blood NUM.
Survey summary PTCL clinical practice recommendations
20th Congress of the European Haematology Association, June 2015, Vienna, Austria Micro-costing study of rituximab subcutaneous injection versus intravenous.
Time to neutrophil engraftment Time to platelet engraftment
A new possible conditionning regimen before Autologous Stem Cell Transplantation for refractory high-grade lymphoma Z-BeEAM (Ibritumomab tiuxetan, Bendamustine,
Adult and Pediatric Dosages Based on Body Weight
Which is the optimal approach: BR or FCR/FR?
STRATEGIES TO PREVENT MEDICATION ERRORS
Clinical Leadership Decision Process
National Resource Center for Late Effects after Cancer Treatment
Haploidentical Transplantation with Post-transplant Cyclophosphamide and Melphalan-based Conditioning– A retrospective Analysis of the First 100 Patients.
Medical Dosage Calculations A Dimensional Analysis Approach
MEDICATION THERAPY MANAGEMENT SERVICES
Chapter 4 Clinical decision making in drug therapy
Allogeneic stem cell transplantation (allo-SCT) is a potentially curative procedure for a variety of malignant and nonmalignant conditions. Historically,
Does One Size Fit All in Obesity Management?
Fludarabine and Busulfan versus Fludarabine, Cyclophosphamide, and Rituximab as Reduced-Intensity Conditioning for Allogeneic Transplantation in Follicular.
Patient charactaristics:
Figure 1 Outline of the AHSCT procedure
Whom should you refer for allogeneic transplantation?
Outcomes in CCG-2961, a Children's Oncology Group Phase 3 Trial for untreated pediatric acute myeloid leukemia: a report from the Children's Oncology Group.
Intravenous Busulfan-Cyclophosphamide as a Preparative Regimen Before Allogeneic Hematopoietic Stem Cell Transplantation for Adult Patients with Acute.
Ematologia, Ospedali Riuniti, Bergamo
Impact of Pre-Transplant Minimal Residual Disease in Patients with AML Undergoing Myeloablative Cord Blood Transplantation  Filippo Milano, MD, PhD, Brent.
Conclusions/Comments
Reduced-Intensity Allogeneic Stem Cell Transplantation in Adults and Children with Malignant and Nonmalignant Diseases: End of the Beginning and Future.
Letermovir(Prevymis™) Guidelines for Inpatient Use
A Single-Center Experience Comparing Alemtuzumab, Fludarabine, and Melphalan Reduced-Intensity Conditioning with Myeloablative Busulfan, Cyclophosphamide,
AML2012 Overview MEC R1 BM d22* R AD(x)E FLAD(x) HAM HA3E FLA BM**
Phase II Trial of 131-Iodine Tositumomab with High-Dose Chemotherapy and Autologous Stem Cell Transplantation for Relapsed Diffuse Large B Cell Lymphoma 
Does Adding Zevalin® to Reduced Intensity Regimen (RIC) of Fludarabine and Melphalan Improve Outcome of Patients with Relapsed/Refractory B-Cell Lymphoma.
AML2012 Overview MEC BM d22* R AD(x)E FLAD(x) HAM HA3E FLA BM**
Reduced-Intensity Conditioning with Fludarabine, Cyclophosphamide, and Rituximab Is Associated with Improved Outcomes Compared with Fludarabine and Busulfan.
Improved Outcomes in Intermediate- and High-Risk Aggressive Non-Hodgkin Lymphoma after Autologous Hematopoietic Stem Cell Transplantation Substituting.
Front-line High-Dose Chemotherapy with Rituximab Showed Excellent Long-Term Survival in Adults with Aggressive Large B-Cell Lymphoma: Final Results of.
Results of 10-Year Single Center Experience with Pharmacokinetics Directed Intravenous Busulfan, Cyclophosphamide and Etoposide Preparative Regimen in.
ASBMT and CBMTG Release Choosing Wisely BMT Recommendations
Fludarabine-Busulfan Reduced-Intensity Conditioning in Comparison with Fludarabine- Melphalan Is Associated with Increased Relapse Risk In Spite of Pharmacokinetic.
Accurate Targeting of Daily Intravenous Busulfan with 8-Hour Blood Sampling in Hospitalized Adult Hematopoietic Cell Transplant Recipients  Rosa F. Yeh,
Long-term Outcome of Hodgkin Disease Patients Following High-Dose Busulfan, Etoposide, Cyclophosphamide, and Autologous Stem Cell Transplantation—A Similar.
Tandem autologous/allogeneic hematopoietic cell transplantation with bortezomib maintenance therapy for high-risk myeloma by Damian J. Green, David G.
by David Deambrosis, Su Han Lum, Ryan M
Timing for HCT Consultation
Presentation transcript:

Roger Williams Medical Center a CharterCare Health Partner Presenter: Mark Curtis RPh Clinical Informatics Pharmacist

 Discuss the current ASBMT Conditioning Regimen Recommendations  Recognize the importance of chemo dosing on outcomes  Demonstrate how a dosing calculator can support doctors, pharmacists and nursing in safe patient therapy  Review the findings from a retrospective review of patients from 2010 through 2014.

 Recognize the current ASBMT Conditioning Regimen Recommendations  Recognize the importance of appropriate chemotherapy dosing  Understand how accurate calculations are needed before the preparation of chemotherapy

Roger Williams Medical Center a CharterCare Health Partner Presenter: Mark Curtis RPh Clinical Informatics Pharmacist Has no financial disclosures to report

DrugsRecommended Dosing Busulfan use AIBW25 for all mg/kg dosing Carmustine use BSA until TBW>120% then use AdjBSA25 Cyclophosphamide use TBW until TBW>120% of IBW then use AIBW25 Cytarabine use BSA (based on TBW) Etoposide mg/kg use AIBW25 for all mg/kg dosing Etoposide BSA use BSA (based on TBW) Fludarabine use BSA (based on TBW) Melphalan use BSA (based on TBW) rATG use TBW for mg/kg dosing Reference:J.Bubalo et al. Biol Blood Marrow Transplant 20 (2014)

REGIMENChemo Drugs Day -6 Day -5 Day -4 Day -3 Day -2 Day -1 DAY 0 BEAM Carmustine 300 mg/m2X Etoposide 100 mg/m2 daily XXXX Cytarabine 100 mg/m2 Q12H XXXX Melphalan 140 mg/m2 X

 Doctors, Nurses, Pharmacists all helped test the calculator  Regimen selection, patient metrics, and dose calculations were all tested for accuracy  Over 80 different patient examples were used for testing  Any discrepancy between the calculator and the manual calculation were reviewed and reconciled

 109 patients transplanted at RWMC between 2010 and 2014  Transplant types included Auto, Allo (MRD/MUD) and Cord Blood  Reviewed dosing variances between the current ASBMT recommendations and the administered dose  Two groups: those with out a variance and those who had a variance

Outcomes were reviewed:  Days to Engraftment of ANC and Platelets  Relapse rates  Survivor rates It is very difficult to confirm cause and effect….

Dosing Variances (Table 1) ConditioningTransplant TypeN Calc Dose Same Calc Dose Variance BEAMAUTO23815 Bu/CyALLO MUD826 Bu/CyALLO MRD202 Flu/BuALLO MUD18315 Flu/BuALLO MRD707 Flu/Cy /TBICord Blood642 Melphalan 140AUTO Melphalan 200AUTO19811 Totals

Dosing Variances by Drug (Table 2) ConditioningDrugsNHighLow Wrong AdjBSA Wrong AIBW BEAM Carmustine BEAM Etoposide BEAM Cytarabine BEAM Melphalan Bu/Cy Busulfan Bu/Cy Cyclophosphamide Flu/Bu Fludarabine Flu/Bu Busulfan Flu/Cy/TBI Fludarabine Flu/Cy/TBI Cyclophosphamide Melphalan 140Melphalan261*15 0 Melphalan 200Melphalan Totals *error in BSA calculation

 Some regimen specific differences in time to engraftment between the two groups.  Possible some differences in relapse and survivor rates  Numbers are not enough in each group to be statistically significant

 The calculator supports consistent and accurate regimen dosing that follows the latest ASBMT recommendations.  There may be some Possible clinical benefit to strictly following the ASBMT recommendations

Kimberly Loftus Transplant Coordinator RWMC Alejandro Carvajal, MD RWMC Todd Roberts MD Medical Director of BMT RWMC

1. Which of the following statements is not true about BMT Conditioning Regimens? A. Dose adjustments are always done using the same method, regardless of the drug being used. B. When Adjusted Ideal Body Weight is used it is the AIBW25. C. BMT conditioning regimen calculations can be complex. D. The intensity of therapy is important to patient outcomes 2. True or False: Using the calculator improves dosing accuracy and may improve outcomes.

1. Which of the following statements is not true about BMT Conditioning Regimens? A. Dose adjustments are always done using the same method, regardless of the drug being used. B. When Adjusted Ideal Body Weight is used it is the AIBW25. C. BMT conditioning regimen calculations can be complex. D. The intensity of therapy is important to patient outcomes 2. True or False: Using the calculator improves dosing accuracy and may improve outcomes.